Chapter 24. Experimental Pharmacology using Isoform-Selective Protein Kinase C Inhibitors

  1. Richard Donnelly MD, PhD, FRCP, FRACP1 and
  2. Edward Horton MD2
  1. Richard Donnelly

Published Online: 13 DEC 2007

DOI: 10.1002/9780470751503.ch24

Vascular Complications of Diabetes: Current Issues in Pathogenesis and Treatment, Second Edition

Vascular Complications of Diabetes: Current Issues in Pathogenesis and Treatment, Second Edition

How to Cite

Donnelly, R. (2005) Experimental Pharmacology using Isoform-Selective Protein Kinase C Inhibitors, in Vascular Complications of Diabetes: Current Issues in Pathogenesis and Treatment, Second Edition (eds R. Donnelly and E. Horton), Blackwell Publishing, Inc., Malden, Massachusetts, USA. doi: 10.1002/9780470751503.ch24

Editor Information

  1. 1

    Division of Vascular Medicine University of Nottingham The Medical School Derby DE22 3DT UK

  2. 2

    Joslin Diabetes Center One Joslin Place Boston MA 02215 USA

Publication History

  1. Published Online: 13 DEC 2007
  2. Published Print: 1 JAN 2005

ISBN Information

Print ISBN: 9781405127851

Online ISBN: 9780470751503

SEARCH

Keywords:

  • protein kinase C;
  • staurosporine;
  • peptide synthesis;
  • experimental data;
  • angiography

Summary

This chapter contains section titled:

  • INTRODUCTION

  • DISCOVERY OF RUBOXISTAURIN (LY333531) — AN ORALLY ACTIVE AND HIGHLY SPECIFIC PKC-β INHIBITOR

  • EFFECTS OF RUBOXISTAURIN IN DIABETIC RETINOPATHY

  • PKC-

  • INHIBITION AND EXPERIMENTAL NEPHROPATHY

  • EFFECTS OF RUBOXISTAURIN IN EXPERIMENTAL DIABETIC NEUROPATHY

  • CLINICAL IMPLICATIONS OF AN ORALLY ACTIVE PKC-

  • INHIBITOR, RUBOXISTAURIN

  • CURRENT ISSUES